(2S)-4-[(2R,13R)-2,13-dihydroxy-13-[(5S)-5-[(2S)-5-[(1S)-1-hydroxyundecyl]oxolan-2-yl]oxolan-2-yl]tridecyl]-2-methyl-2H-furan-5-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2S)-4-[(2R,13R)-2,13-dihydroxy-13-[(5S)-5-[(2S)-5-[(1S)-1-hydroxyundecyl]oxolan-2-yl]oxolan-2-yl]tridecyl]-2-methyl-2H-furan-5-one
• 化学式: C₃₇H₆₆O₇
• 分子量: 622.9
• InChiKey: MBABCNBNDNGODA-WIGKUCHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.7
• 重原子数：
  44
• 可旋转键数：
  25
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Cancer Treatment by Simultaneous Targeting Energy Metabolism and Intracellular pH
  申请人：Deutsches Krebsforschungszentrum

  公开号：US20190321311A1

  公开（公告）日：2019-10-24

  The present invention relates to an inhibitor of mitochondrial respiration for use in treatment of cancer with a proton ionophore and relates to a proton ionophore for use in treatment of cancer with an inhibitor of mitochondrial respiration. The present invention further relates to a combined preparation for simultaneous, separate or sequential use comprising (i) an inhibitor of mitochondrial respiration and (ii) a proton ionophore, to said combined preparation for use in treatment of cancer, and to kits and methods related thereto.